STOCK TITAN

Lineage Cell Therapeutics, Inc. - LCTX STOCK NEWS

Welcome to our dedicated page for Lineage Cell Therapeutics news (Ticker: LCTX), a resource for investors and traders seeking the latest updates and insights on Lineage Cell Therapeutics stock.

Lineage Cell Therapeutics, Inc. (Symbol: LCTX) is a clinical-stage biotechnology company that is pioneering the development and commercialization of novel therapies designed to address degenerative diseases. With a foundation built on pluripotent cell technology, Lineage Cell's innovative approach leverages cells capable of transforming into any type of cell in the human body. This groundbreaking capability allows for therapies aimed at regenerating or replacing damaged cells and tissues, providing hope for conditions that currently have no cure.

The company's pipeline is robust and diverse, encompassing several key product candidates:

  • OpRegen: A retinal pigment epithelium transplant therapy targeting dry age-related macular degeneration, a leading cause of vision loss among the elderly.
  • OPC1: An oligodendrocyte progenitor cell therapy designed to treat acute spinal cord injuries by promoting cell replacement and recovery.
  • VAC2: An allogeneic cancer immunotherapy utilizing antigen-presenting dendritic cells to fight non-small cell lung cancer.
  • ANP1: A promising therapy involving the transplant of allogeneic auditory neuron progenitor cells to combat hearing loss.
  • PNC1: An innovative approach using allogeneic photoreceptor cell transplants aimed at treating vision loss.

Lineage Cell Therapeutics is committed to addressing large unmet medical needs through its cutting-edge technologies. The company's clinical-stage programs are supported by a premier collection of pluripotent cell assets, positioning it at the forefront of regenerative medicine.

Recent achievements include significant progress in clinical trials, strategic partnerships, and advancements in their product development pipeline. Financially, the company remains poised for growth with a clear focus on expanding its therapeutic offerings and enhancing shareholder value.

Stay informed with the latest updates and developments at Lineage Cell Therapeutics as they continue to advance their mission of transforming the treatment landscape for degenerative diseases.

Rhea-AI Summary
Lineage Cell Therapeutics, Inc. will report its third quarter 2023 financial and operating results on November 9, 2023. A conference call and webcast will be held to discuss the results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
conferences earnings
-
Rhea-AI Summary
Lineage Cell Therapeutics to present at Eyecelerator 2023 and announces positive results from clinical study
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.72%
Tags
-
Rhea-AI Summary
Lineage Cell Therapeutics announces issuance of U.S. Patent for Large Scale Production of Retinal Pigment Epithelial Cells
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.48%
Tags
none
Rhea-AI Summary
Lineage Cell Therapeutics presents positive results of Phase 1/2a study of OpRegen at EURETINA Congress
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10%
Tags
-
Rhea-AI Summary
Lineage Cell Therapeutics CEO to present at Cantor Fitzgerald 2023 Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.53%
Tags
conferences
-
Rhea-AI Summary
Lineage Cell Therapeutics announces positive results from Phase 1/2a study of RG6501 (OpRegen) in treating age-related macular degeneration (AMD)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
Rhea-AI Summary
Lineage Cell Therapeutics' Senior VP to present at ISRT Network Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.21%
Tags
conferences
-
Rhea-AI Summary
Lineage Cell Therapeutics announced initiation of development activities for a novel hypoimmune induced pluripotent stem cell line under its agreement with Eterna Therapeutics. The company has finalized specific gene edits for the initial cell lines, including targeted deletion and insertion of genes to reduce immunogenicity and prevent rejection. Lineage expects these edits to expand the cell lines' utility and differentiate them from competitors' products. The collaboration aims to capitalize on cell engineering and editing technologies to create superior cell transplant therapies. Eterna will conduct gene-editing activities and provide materials to Lineage under the agreement. Lineage has an option to obtain an exclusive license for the gene-edited cell lines for CNS diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.17%
Tags
partnership
-
Rhea-AI Summary
Lineage Cell Therapeutics, Inc. CEO to present at Baird's 2023 Global Healthcare Conference and H.C. Wainwright 25th Annual Global Investment Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.21%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags

FAQ

What is the current stock price of Lineage Cell Therapeutics (LCTX)?

The current stock price of Lineage Cell Therapeutics (LCTX) is $0.558 as of December 20, 2024.

What is the market cap of Lineage Cell Therapeutics (LCTX)?

The market cap of Lineage Cell Therapeutics (LCTX) is approximately 118.5M.

What does Lineage Cell Therapeutics, Inc. specialize in?

Lineage Cell Therapeutics specializes in developing and commercializing novel cell therapies for treating degenerative diseases.

What are the main product candidates of Lineage Cell Therapeutics?

The main product candidates include OpRegen, OPC1, VAC2, ANP1, and PNC1.

What is OpRegen?

OpRegen is a retinal pigment epithelium transplant therapy aimed at treating dry age-related macular degeneration.

How does Lineage Cell Therapeutics utilize pluripotent cells?

Lineage Cell Therapeutics uses pluripotent cells capable of becoming any cell type to regenerate or replace affected cells and tissues.

What is OPC1 designed to treat?

OPC1 is an oligodendrocyte progenitor cell therapy for treating acute spinal cord injuries.

What type of cancer is VAC2 targeting?

VAC2 targets non-small cell lung cancer using allogeneic cancer immunotherapy.

What recent achievements has Lineage Cell Therapeutics made?

Recent achievements include progress in clinical trials, strategic partnerships, and advancements in their product development pipeline.

What is ANP1?

ANP1 is a therapy involving the transplant of allogeneic auditory neuron progenitor cells to treat hearing loss.

What is the financial outlook of Lineage Cell Therapeutics?

Lineage Cell Therapeutics is focused on growth, expanding its therapeutic offerings, and enhancing shareholder value.

Where can I find the latest updates on Lineage Cell Therapeutics?

The latest updates and developments can be found on their website and through financial news platforms.

Lineage Cell Therapeutics, Inc.

NYSE:LCTX

LCTX Rankings

LCTX Stock Data

118.47M
219.17M
0.44%
50.56%
8.44%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
CARLSBAD